Exact Mass: 433.25765800000005
Exact Mass Matches: 433.25765800000005
Found 107 metabolites which its exact mass value is equals to given mass value 433.25765800000005
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N-Eicosapentaenoyl Methionine
C25H39NO3S (433.26505040000006)
N-eicosapentaenoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Methionine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Ulipristal
C28H35NO3 (433.26168000000007)
Ser Val Thr Lys
C18H35N5O7 (433.25363600000003)
Ile Lys Ser Ser
C18H35N5O7 (433.25363600000003)
Ile Ser Lys Ser
C18H35N5O7 (433.25363600000003)
Ile Ser Ser Lys
C18H35N5O7 (433.25363600000003)
Lys Ile Ser Ser
C18H35N5O7 (433.25363600000003)
Lys Leu Ser Ser
C18H35N5O7 (433.25363600000003)
Lys Ser Ile Ser
C18H35N5O7 (433.25363600000003)
Lys Ser Leu Ser
C18H35N5O7 (433.25363600000003)
Lys Ser Ser Ile
C18H35N5O7 (433.25363600000003)
Lys Ser Ser Leu
C18H35N5O7 (433.25363600000003)
Lys Ser Thr Val
C18H35N5O7 (433.25363600000003)
Lys Ser Val Thr
C18H35N5O7 (433.25363600000003)
Lys Thr Ser Val
C18H35N5O7 (433.25363600000003)
Lys Thr Val Ser
C18H35N5O7 (433.25363600000003)
Lys Val Ser Thr
C18H35N5O7 (433.25363600000003)
Lys Val Thr Ser
C18H35N5O7 (433.25363600000003)
Leu Lys Ser Ser
C18H35N5O7 (433.25363600000003)
Leu Ser Lys Ser
C18H35N5O7 (433.25363600000003)
Leu Ser Ser Lys
C18H35N5O7 (433.25363600000003)
Ser Ile Lys Ser
C18H35N5O7 (433.25363600000003)
Ser Ile Ser Lys
C18H35N5O7 (433.25363600000003)
Ser Lys Ile Ser
C18H35N5O7 (433.25363600000003)
Ser Lys Leu Ser
C18H35N5O7 (433.25363600000003)
Ser Lys Ser Ile
C18H35N5O7 (433.25363600000003)
Ser Lys Ser Leu
C18H35N5O7 (433.25363600000003)
Ser Lys Thr Val
C18H35N5O7 (433.25363600000003)
Ser Lys Val Thr
C18H35N5O7 (433.25363600000003)
Ser Leu Lys Ser
C18H35N5O7 (433.25363600000003)
Ser Leu Ser Lys
C18H35N5O7 (433.25363600000003)
Ser Ser Ile Lys
C18H35N5O7 (433.25363600000003)
Ser Ser Lys Ile
C18H35N5O7 (433.25363600000003)
Ser Ser Lys Leu
C18H35N5O7 (433.25363600000003)
Ser Ser Leu Lys
C18H35N5O7 (433.25363600000003)
Ser Thr Lys Val
C18H35N5O7 (433.25363600000003)
Ser Thr Val Lys
C18H35N5O7 (433.25363600000003)
Ser Val Lys Thr
C18H35N5O7 (433.25363600000003)
Thr Lys Ser Val
C18H35N5O7 (433.25363600000003)
Thr Lys Val Ser
C18H35N5O7 (433.25363600000003)
Thr Ser Lys Val
C18H35N5O7 (433.25363600000003)
Thr Ser Val Lys
C18H35N5O7 (433.25363600000003)
Thr Val Lys Ser
C18H35N5O7 (433.25363600000003)
Thr Val Ser Lys
C18H35N5O7 (433.25363600000003)
Val Lys Ser Thr
C18H35N5O7 (433.25363600000003)
Val Lys Thr Ser
C18H35N5O7 (433.25363600000003)
Val Ser Lys Thr
C18H35N5O7 (433.25363600000003)
Val Ser Thr Lys
C18H35N5O7 (433.25363600000003)
Val Thr Lys Ser
C18H35N5O7 (433.25363600000003)
Val Thr Ser Lys
C18H35N5O7 (433.25363600000003)
Aplidic acid C
C28H35NO3 (433.26168000000007)
NA 28:11;O2
C28H35NO3 (433.26168000000007)
tert-butyl N-[(1S)-2-[(1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexan-2-yl]-1-(3-hydroxy-1-adamantyl)-2-oxoethyl]carbamate
C23H35N3O5 (433.25765800000005)
Ulipristal
C28H35NO3 (433.26168000000007)
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03X - Other sex hormones and modulators of the genital system > G03XB - Progesterone receptor modulators G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03A - Hormonal contraceptives for systemic use > G03AD - Emergency contraceptives C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C1891 - Progesterone Antagonist
N-[2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-1H-imidazole-5-carboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C23H35N3O5 (433.25765800000005)
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C23H35N3O5 (433.25765800000005)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C23H35N3O5 (433.25765800000005)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C23H35N3O5 (433.25765800000005)
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propanoyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6R,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(5R,6R,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(5R,6S,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C23H35N3O5 (433.25765800000005)
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1-oxopropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]propanamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C23H35N3O5 (433.25765800000005)
N-[(4R,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(4R,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7R,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(4R,7S,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(4R,7S,8R)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(4S,7R,8S)-5-acetyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(5R,6R,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6S,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6S,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
N-[(5S,6R,9S)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C23H35N3O5 (433.25765800000005)
2-aminoethyl [3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-2-hydroxypropyl] hydrogen phosphate
C21H40NO6P (433.2593110000001)
N-Formyl-norleucyl-leucyl-phenylalanyl-methylester
C23H35N3O5 (433.25765800000005)
Etrinabdione
C28H35NO3 (433.26168000000007)
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2]. Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2].
(2r,3r,4s,5s)-2-{[(1s,2s,3r,4s,6r)-4,6-diamino-3-{[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-4-(methylamino)oxane-3,5-diol
C18H35N5O7 (433.25363600000003)